Here is an excerpt from the latest 10Q:
As of September 30, 2013, we had experienced total net losses since inception of $199,874,118, stockholders' deficit of $27,642,393 and a net working capital deficit of approximately $10,124,000. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as we execute our current business plan. The cash and cash equivalents available at September 30, 2013 will not provide sufficient working capital to meet our anticipated expenditures for the next twelve months. From January 2013 through September 30, 2013 we liquidated 285,000 shares of our Navidea Biopharmaceuticals, Inc. ("Navidea" AMEX:NAVB) common stock for total proceeds of $861,618. We used these proceeds to settle our lawsuit with Children's Hospital and to meet our day-to-day obligations and continue to comply with our regulatory reporting requirements. We believe that the approximately $26,000 in cash and cash equivalents available as of November 1, may enable us to meet our anticipated cash expenditures through November 2013.
hispanicbusiness.com |
